Proteases
Proteases, also known as peptidases or proteolytic enzymes, consists of a large number of enzymes catalyzing the hydrolysis of peptide bonds and subsequently resulting in the degradation of protein substrates into amino acids. Proteases are involved in a wide range of human diseases, including cancer, neurodegenerative disorders, inflammatory diseases and cardiovascular diseases. Thus numerous proteases inhibitors (small molecules and proteins) have been identified to block activity of proteases. Proteases inhibitors can be classified into different types based on the class of proteases they inhibit through two general mechanisms, irreversible “trapping” reactions and reversible tight-binding reactions. Proteases inhibitors have been used as diagnostic or therapeutic agents for the treatment of proteases-related diseases.
- A4056 AT13387Target: HSP90Summary: Hsp90 inhibitor
- A4057 AUY922 (NVP-AUY922)1 CitationTarget: HSP90Summary: Potent Hsp90 inhibitor
- A4058 BIIB021Target: HSP90Summary: Hsp90 inhibitor,selective and competitive
- A4061 IPI-504 (Retaspimycin hydrochloride)3 CitationTarget: HSP90Summary: Hsp90 inhibitor,novel, potent,selective
- A4062 KW-2478Target: HSP90Summary: Potent Hsp90 inhibitor, novel, non-ansamycin,
- A4064 NVP-BEP800Target: HSP90Summary: Oral Hsp90β inhibitor, novel, fully synthetic
- A4065 PF-04929113 (SNX-5422)Target: HSP90Summary: Hsp90 inhibitor,potent and selective
- A4388 XL-8881 CitationTarget: HSP90Summary: Hsp90 inhibitor
- A2213 17-DMAG (Alvespimycin) HCl1 CitationTarget: HSP90Summary: Hsp90 inhibitor
- B7393 GeduninTarget: HSP90Summary: naturally occurring Hsp90 inhibitor